Drugs / FL058
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05058105 | Oct 2020 → Feb 2021 | — | Qilu Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05055687 | Jul 2020 | — | Qilu Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05058118 | Dec 2019 → Jun 2020 | — | Qilu Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05060419 | Oct 2021 → Apr 2022 | acute pyelonephritis | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FL058 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05055687 ↗ |
| Action | Inhibit | “FL058 is a novel diazabicyclooctane β-lactamase inhibitor.” PMID 38054726 ↗ Dec 2023 |
| Modality | Small molecule | “FL058 is a novel diazabicyclooctane β-lactamase inhibitor.” PMID 38054726 ↗ Dec 2023 |
| Route | Intravenous | “single-multiple intravenous doses of FL058” NCT05055687 ↗ |